1-6 of 6
Peter U. Park
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors

Michael Rigby, Gavin Bennett, Liuhong Chen, Gemma E. Mudd, Helen Harrison, Paul J. Beswick, Katerine Van Rietschoten, Sophie M. Watcham, Heather S. Scott, Amy N. Brown, Peter U. Park, Carly Campbell, Eric Haines, Johanna Lahdenranta, Michael J. Skynner, Phil Jeffrey, Nicholas Keen, Kevin Lee
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (12): 1747–1756.
https://doi.org/10.1158/1535-7163.MCT-21-0875
Published: 02 December 2022
View article titled, BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors
Open the PDF for BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Mao Yin, Joshua D. Thomas, Susan M. Clardy, Patrick R. Conlon, Cheri A. Stevenson, Alex Uttard, LiuLiang Qin, Dmitry R. Gumerov, Elena Ter-Ovanesyan, Charlie Bu, Alex J. Johnson, Venu R. Gurijala, Dennis McGillicuddy, Michael J. DeVit, Laura L. Poling, Marina Protopopova, Ling Xu, Qingxiu Zhang, Peter U. Park, Donald A. Bergstrom, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (5): 885–895.
https://doi.org/10.1158/1535-7163.MCT-20-0166
Published: 01 May 2021
View article titled, Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
Open the PDF for Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect in another window
Includes: Supplementary data
Journal Articles

The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

Natalya D. Bodyak, Rebecca Mosher, Aleksandr V. Yurkovetskiy, Mao Yin, Charlie Bu, Patrick R. Conlon, Damon R. Demady, Michael J. DeVit, Dmitry R. Gumerov, Venu R. Gurijala, Winnie Lee, Dennis McGillicuddy, Peter U. Park, Laura L. Poling, Marina Protopova, LiuLiang Qin, Cheri A. Stevenson, Elena Ter-Ovanesyan, Alex Uttard, Dongmei Xiao, Jian Xu, Ling Xu, Donald A. Bergstrom, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (5): 896–905.
https://doi.org/10.1158/1535-7163.MCT-20-0183
Published: 01 May 2021
View article titled, The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
Open the PDF for The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b in another window
Includes: Supplementary data
Journal Articles

Abstract C061: BT8009, a Bicycle Toxin Conjugate targeting Nectin-4, shows target selectivity, and efficacy in preclinical large and small tumor models

Michael Rigby, Gavin Bennett, Liuhong Chen, Gemma Mudd, Paul Beswick, Helen Harrison, Sophie Watcham, Heather Allen, Amy Brown, Katerine Van Rietschoten, Philip Jeffrey, Peter U Park, Eric Haines, Nicholas Keen, Johanna Lahdenranta
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C061.
https://doi.org/10.1158/1535-7163.TARG-19-C061
Published: 01 December 2019
View article titled, Abstract C061: BT8009, a Bicycle Toxin Conjugate targeting Nectin-4, shows target selectivity, and efficacy in preclinical large and small tumor models
Journal Articles

Abstract C238: Polyacetal polymer-based anti-HER2 antibody-drug conjugate employing cysteine bioconjugation through thioether linkage allows a high drug loading of dolastatin-derived payload with excellent pharmacokinetics and potent anti-tumor activity.

Joshua Thomas, Alex Yurkovetskiy, Natalya Bodyak, Mao Yin, Patrick Conlon, Cheri Stevenson, Alex Uttard, Liu Qin, Dmitry Gumerov, Elena Ter-Ovaneysan, Michael DeVit, Laura L. Poling, Peter U. Park, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C238.
https://doi.org/10.1158/1535-7163.TARG-13-C238
Published: 01 November 2013
View article titled, Abstract C238: Polyacetal polymer-based anti-HER2 antibody-drug conjugate employing cysteine bioconjugation through thioether linkage allows a high drug loading of dolastatin-derived payload with excellent pharmacokinetics and potent anti-tumor activity.
Journal Articles

Abstract B209: The CD37-targeting ADC IMGN529 combines the potent anticancer activity of K7153A antibody with efficient maytansinoid delivery.

Katharine C. Lai, Hans K. Erickson, Xiuxia Sun, Peter U. Park, Jutta Deckert, Min Li, Yong Yi, Jan Pinkas, Jennifer A. Coccia, Sara Nadworny
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B209.
https://doi.org/10.1158/1535-7163.TARG-11-B209
Published: 12 November 2011
View article titled, Abstract B209: The CD37-targeting ADC IMGN529 combines the potent anticancer activity of K7153A antibody with efficient maytansinoid delivery.